Natera reported preliminary Q4 revenue driven by Signatera MRD test sales and processed over 923,600 tests in Q4, with oncology and MRD volumes up substantially year‑over‑year; the company guided to robust 2025 revenue growth. Natera highlighted oncology testing and MRD expansion as primary growth engines. Guardant Health posted preliminary Q4 revenue growth of ~39%, citing sharp increases in oncology and Shield screening tests; full‑year 2025 revenue approached $981 million. Both companies attributed gains to higher test volumes, expanded clinical adoption and scaling of screening and minimal residual disease assays. The results emphasize strengthening commercial traction for blood‑based oncology diagnostics, a growing payer and provider focus area tied to earlier detection, therapy selection and MRD‑guided treatment decisions.